Can psoriasis patients safely cut their medication dose in half?
NCT ID NCT04340076
Summary
This study tested whether carefully reducing the dose of newer psoriasis medications (IL17 or IL23 inhibitors) works as well as continuing the standard dose. It involved 244 patients whose psoriasis was already well-controlled. The goal was to see if lower doses could maintain control, potentially improving safety and lowering costs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Maria Middelares
Ghent, Belgium
-
AZ St Lucas
Ghent, Belgium
-
Amphia Hospital
Breda, Netherlands
-
Bravis hospital
Bergen op Zoom, Netherlands
-
CHU Liege
Liège, Belgium
-
Catharina hospital
Eindhoven, Netherlands
-
Dermatologie Maldegem
Maldegem, Belgium
-
Erasmus MC
Rotterdam, Netherlands
-
Ghent University Hospital
Ghent, 9000, Belgium
-
Maastricht UMC
Maastricht, Netherlands
-
Máxima Medisch Centrum
Veldhoven, Netherlands
-
Radboudumc
Nijmegen, 6500HB, Netherlands
-
Slingeland hospital
Doetinchem, Netherlands
-
UCL Saint Luc
Leuven, Belgium
-
ULB Erasme
Brussels, Belgium
-
UMC Groningen
Groningen, Netherlands
-
UMC Utrecht
Utrecht, Netherlands
-
UZ Leuven
Leuven, Belgium
-
Ziekenhuisgroep Twente
Almelo, Netherlands
Conditions
Explore the condition pages connected to this study.